Wednesday , December 8 2021

Iterum Therapeutics (ITRM) PT Set at $ 20.00 from Needham & Compani LLC



[ad_1]

Needham & Compani LLC has set a target of $ 20.00 Iterum Therapy (Nasdaq: ITRM) in a report published Wednesday morning. The firm currently has a purchasing rating.

Several other analysts have recently published reports about the company. Zacks Investment Research on Friday, November 9th, reduced Iterum Therapeutics from rating rating to sales estimation in the survey. Gabelli repeated the purchase of Iterum Therapeutics's rating of stocks in a survey on Monday, October 22. An investment analyst estimated shares with a rating for maintenance and five issued a rating for the purchase of shares of the company. The campaign currently has a consensus buying rating and an average price of $ 20.75.

The shares of Iterum Therapeutics traded at $ 0.11 on Wednesday, reaching $ 5.81. 11,530 stocks of shares traded, compared with an average volume of 12,187. Iterum Therapeutics has a low year of $ 5.31 and a year high of $ 13.00. The company has a debt ratio of 0.15, a quick ratio of 11.53 and a current ratio of 14.05.

Iterum Therapy (Nasdaq: ITRM) last published quarterly earnings results on Wednesday, November 14th. The company posted a $ 1.24 earnings per share (EPS) for a quarter, exceeding the Zacks Consensus estimate of $ 1.97 for $ 0.73. The firm had $ 0.25 million revenue per quarter. On average, research analysts in actions expect that Iterum Therapeutics will become -10.82 EPS for the current year.

In related news, Mark Chin has bought 58,000 shares of this stock in a transaction dated Tuesday, October 30th. The shares were bought at an average price of $ 6.10 per share, with a total value of $ 353,800.00. This acquisition was disclosed in a legal filing with the SEC, which can be accessed via this link. During the last ninety days, insiders have bought 60,000 shares of the company, worth $ 374,020.

Hedge funds recently bought and sold the company's shares. Frazier Management LLC bought a new position in Iterum Therapeutics in the second quarter worth approximately $ 16,414,000. Granahan Investment Management Inc. has bought a new share in Iterum Therapeutics in the second quarter worth about $ 2,570,000. Millennium Management LLC has bought a new share in the Iterum Therapeutics campaign for the 2nd Quarter, valued at approximately $ 1,867,000. Tiverton Asset Management LLC bought a new stake in Iterum Therapeutics during the II quarter worth approximately 1,529,000 USD. Finally, Neuburg Advisers LLC bought a new share in the Iterum Therapeutics campaign for the 2nd Quarter worth $ 675,000. 47.63% of shares are currently owned by hedge funds and other institutional investors.

Company Profile Iterum Therapeutics

Iterum Therapeutics plc, a pharmaceutical company in the clinical stage, is committed to the development of anti-infective agents for pathogens resistant to drugs in Ireland and the United States. The company develops a sulopenem, a peneal antiinfective compound with oral and IV formulations found in clinical trials of the third phase for the treatment of adults in non-complicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Further reading: How to calculate the internal value of the action

Recommendations of analysts for Iterum Therapy (Nasdaq: ITRM)

You get news and ratings for Iterum Therapeutics Daili – Enter your email address below to get a concise daily review of the latest news and analysts for Iterum Therapeutics and related companies with the FREE Daily MarketBeat.com newsletter.

[ad_2]
Source link